Full Press Release Details
Pharmaceuticals to Present at the BIO CEO Investor Conference
VICTORIA, British Columbia--(BUSINESS WIRE)--January 29, 2015--Aurinia
Pharmaceuticals, Inc., (NASDAQ: AUPH / TSX: AUP) today announced that
its President and Chief Executive Officer Stephen Zaruby will present a
corporate overview of the company at the BIO CEO Investor Conference,
taking place February 9th-10th in New York at the Waldorf-Astoria Hotel.
The presentation will also be available using the webcast link below.
Aurinia Presentation Details
Time: 3:00 p.m. Eastern Standard Time
Waldorf-Astoria Hotel
Aurinia is a clinical stage
pharmaceutical company focused on the global nephrology market. It is
currently in the recruitment and enrollment phase of its Phase 2b
clinical trial to evaluate the efficacy of its drug, voclosporin, as a
treatment for lupus nephritis (LN). LN is an inflammation of the
kidneys, that if inadequately treated can lead to end-stage renal
disease, making LN a serious and potentially life-threatening condition.
Visit www.auriniapharma.com for more information.
Aurinia Pharmaceuticals, Inc.
Zaruby, 250-708-4293
President & Chief Executive Officer
Michael R. Martin, 250-708-4272